First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

Related Keywords

Berlin ,Germany ,Irvine ,California ,United States ,Oregon ,Andreas Mansel ,Adam Slansky ,Volkan Granit ,Nizar Chahin ,Samantha Masterson ,James Howard ,Marc Feinberg ,Boca Raton ,Michael Benatar ,Danielle Ellis ,Tuan Vu ,Tahseen Mozaffar ,Gregory Sahagian ,Neurology Associates ,Oregon Health ,Study Team ,Science University ,University Of California ,National Institutes Of Health ,Neurocure Clinical Research Center ,Myasthenia Gravis Foundation Of America ,University Of South Florida ,Neurology Center ,National Institute Of Neurological Disorders ,University Of Miami ,Chief Medical Officer ,North Carolina ,Chapel Hill ,Myasthenia Gravis Foundation ,Lancet Neurology ,Antigen Receptort Cell ,Myasthenia Gravis ,Southern California ,South Florida ,National Institutes ,National Institute ,Neurological Disorders ,Autoimmunity ,Fell ,Clinical Trial ,Eurology ,Na ,Herapeutics ,Ntigen ,Biotechnology ,Flood ,Chemotherapy ,Chimeric Antigen Receptor ,Hronic ,Efficacy ,Muscle ,Neurological Disease ,Ncology ,Eceptor ,Research ,T Cell ,